Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

darusentan

Known as: (+)-(S)-2-((4,6-dimethoxy-2-pyrimidinyl)oxy)-3-methoxy-3,3-diphenylpropionic acid, benzenepropanoic acid, alpha-((4,6-dimethoxy-2-pyrimidinyl)oxy)-beta-methoxy-beta-phenyl-, (S)- 
National Institutes of Health

Related topics

Related topics

4 relations

Broader (3)

Endothelin receptor antagonistPhenylpropionatesPyrimidines

Narrower (1)

LU 135252

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2010
Highly Cited
2010
Divergent Results Using Clinic and Ambulatory Blood Pressures: Report of a Darusentan-Resistant Hypertension Trial
Patients with resistant hypertension are at increased risk for cardiovascular events. The addition of new treatments to existing… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • figure 4
Review
2010
Review
2010
Benefits from Treatment and Control of Patients with Resistant Hypertension
Resistant hypertension is commonly found in everyday clinical practice. However, the risks of resistant hypertension, as well as… Expand
  • figure 1
  • figure 3
  • figure 2
  • figure 4
  • table 1
Highly Cited
2010
Highly Cited
2010
Evaluation of the endothelin receptor antagonists ambrisentan, darusentan, bosentan, and sitaxsentan as substrates and inhibitors of hepatobiliary transporters in sandwich-cultured human hepatocytes.
To evaluate potential mechanisms of clinical hepatotoxicity, 4 endothelin receptor antagonists (ERAs) were examined for substrate… Expand
  • figure 1
  • table 1
  • figure 2
  • figure 4
  • figure 3
Highly Cited
2009
Highly Cited
2009
A selective endothelin-receptor antagonist to reduce blood pressure in patients with treatment-resistant hypertension: a randomised, double-blind, placebo-controlled trial
BACKGROUND Hypertension cannot always be adequately controlled with available drugs. We investigated the blood-pressure-lowering… Expand
  • figure 1
  • table 1
  • figure 2
  • table 2
  • figure 3
Highly Cited
2007
Highly Cited
2007
Efficacy and Safety of Darusentan in Patients With Resistant Hypertension: Results From a Randomized, Double‐Blind, Placebo‐Controlled Dose‐Ranging Study
In this phase 2, randomized, double‐blind, placebo‐controlled forced dose‐titration study, 115 patients with resistant… Expand
Review
2006
Review
2006
Profile of Past and Current Clinical Trials Involving Endothelin Receptor Antagonists: The Novel “-Sentan” Class of Drug
Since its initial characterization in 1988, over 18,236 papers, including 2,485 reviews, have been published in the endothelin… Expand
  • figure 1
  • figure 1
  • figure 1
Highly Cited
2004
Highly Cited
2004
Long-term effects of darusentan on left-ventricular remodelling and clinical outcomes in the EndothelinA Receptor Antagonist Trial in Heart Failure (EARTH): randomised, double-blind, placebo…
BACKGROUND Endothelin-receptor blockade provides haemodynamic benefit in experimental and clinical heart failure. We aimed to… Expand
Highly Cited
2004
Highly Cited
2004
Role of Podocytes for Reversal of Glomerulosclerosis and Proteinuria in the Aging Kidney After Endothelin Inhibition
The cause of focal-segmental glomerulosclerosis as a consequence of physiological aging, which is believed to be inexorable, is… Expand
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Highly Cited
2002
Highly Cited
2002
Darusentan: an effective endothelinA receptor antagonist for treatment of hypertension.
BACKGROUND The antihypertensive efficacy and safety of darusentan, a new selective endothelin, antagonist was investigated… Expand
Highly Cited
2002
Highly Cited
2002
Hemodynamic and Neurohumoral Effects of Selective Endothelin A (ETA) Receptor Blockade in Chronic Heart Failure: The Heart Failure ETA Receptor Blockade Trial (HEAT)
Background—The endothelin (ET-1) system is activated in chronic heart failure (CHF). Whether, what type, and what degree of… Expand
  • table 1
  • table 2
  • table 3
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy, Terms of Service, and Dataset License
ACCEPT & CONTINUE